EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials

Daniel G Brieger, Karan Rao, Vinayak Nagaraja, Ravinay Bhindi, Usaid K Allahwala

Vascular Pharmacology · 2025

DOI: 10.1016/j.vph.2025.107500 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Vascular Pharmacology, 2025. Verfasst von Daniel G Brieger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia; University of Sydney, Camperdown, Sydney, NSW, Australia. Electronic address: daniel…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Platelet Glycoprotein GPIIb-IIIa Complex, Platelet Aggregation Inhibitors, Coronary Artery Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glycoprotein IIb/IIIa inhibitors (GPIs) improve 30-day outcomes when used as an adjunct to percutaneous coronary intervention (PCI) in acute coronary syndromes, but their role in stable coronary artery disease (CAD) remains uncertain in the context of modern stents and oral antiplatelet therapy. METHODOLOGY: A systematic search of PubMed, EMBASE, Central and clinicaltrials.gov databases was conducted from inception to October 2022. Randomised trials comparing GPI to placebo in elective PCI were included. Outcomes included target vessel revascularisation (TVR), stent thrombosis (ST) and a composite of TVR, myocardial infarction and death (MACE) at 30-days and 6-12 months. Bleeding was assessed using Thrombolysis In Myocardial Infarction bleeding score or equivalent. A random-effects model was used for all analyses. RESULTS: Of 2375 abstracts screened, 16 studies (6428 patients) were included. GPIs significantly reduced 30-day MACE (risk ratio [RR] 0.58, 95 % CI, 0.39-0.86, p < 0.01; number needed to treat = 33), intermediate-term MACE at 6-12 months (RR 0.67; 95 % CI, 0.49-0.92; p = 0.01) and ST (RR 0.29, 95 % CI, 0.10-0.83, p = 0.02). There was no significant difference in TVR or major bleeding, although minor bleeding was increased (RR 1.72, 95 % CI, 1.14-2.61, p = 0.01, number needed to harm = 77). Meta-regression suggested that the benefit of GPIs has diminished over time. CONCLUSION: GPI use during elective PCI reduces MACE and ST whilst increasing minor bleeding. The observed benefit appears to have waned over time, highlighting the importance of selective use in patients at low bleeding risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet Aggregation InhibitorsCoronary Artery DiseaseHumansRandomized Controlled Trials as TopicTreatment OutcomeHemorrhageRisk FactorsTime FactorsRisk AssessmentMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

Coronary artery diseaseGlycoprotein iib/iiia inhibitorsPercutaneous coronary intervention

Substanzen

Platelet Glycoprotein GPIIb-IIIa ComplexPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia; University of Sydney, Camperdown, Sydney, NSW, Australia. Electronic address: daniel.brieger@sydney.edu.au.
  • Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia; University of Sydney, Camperdown, Sydney, NSW, Australia.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Zitieren

APA

Brieger, D. G., Rao, K., Nagaraja, V., Bhindi, R., & Allahwala, U. K. (2025). The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2025.107500

Vancouver

Brieger DG, Rao K, Nagaraja V, Bhindi R, Allahwala UK. The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials. Vascular Pharmacology. 2025. doi:10.1016/j.vph.2025.107500

BibTeX
@article{Brieger2025,
  author = {Brieger, Daniel G and Rao, Karan and Nagaraja, Vinayak and Bhindi, Ravinay and Allahwala, Usaid K},
  title = {The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials},
  journal = {Vascular Pharmacology},
  year = {2025},
  doi = {10.1016/j.vph.2025.107500}
}
Kostenlos starten →